ArticlePsychological assessment2021
Elaborating on the longitudinal measurement invariance and construct validity of the triarchic psychopathy scales from the Multidimensional Personality Questionnaire.
Article in Psychological assessment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Hungry Ghosts Eat Casino Chips: Associations Between Dispositional Greed and Gambling.Personality & social psychology bulletin · 2026Article
- Longitudinal trajectory classes and correlates of the Multidimensional Personality Questionnaire-triarchic psychopathy scales from adolescence to young adulthood.Development and psychopathology · 2025Article
- Longitudinal Associations between Parenting Practices and Children's Later Decision-Making Competence.Applied developmental science · 2025Article
- Disentangling the relationship between posttraumatic stress disorder, criminogenic risk, and criminal history among veterans.Law and human behavior · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 4 countries.
Funding
Abstract
Because the construct of psychopathy is of chief interest across different disciplines, spanning developmental, clinical, and forensic psychology, its assessment bears far-reaching implications. One prominent contemporary conceptualization of psychopathy, the Triarchic Model, posits that a psychopathic personality encompasses three phenotypic constructs: boldness, meanness, and disinhibition. Recently, triarchic scales have been derived based on items from the Multidimensional Personality Questionnaire (MPQ), and the psychometric characteristics of this approach (MPQ-triarchic [MPQ-Tri]) are promising. The present study examined the longitudinal measurement invariance and the construct validity of the MPQ-Tri scales in a large and diverse high-risk sample (N = 716) across four time points from age 16-25. First, we report and discuss implications of confirmatory and exploratory factor analyses of the MPQ-Tri scales. Next, we report evidence for longitudinal configural and partial scalar invariance. In addition, in line with previous studies, MPQ-Boldness showed relatively higher levels of rank-order and mean-level stability compared to MPQ-Meanness and Disinhibition. Finally, in terms of construct validity, the MPQ-Tri scales showed a pattern of association with external correlates across internalizing and externalizing domains that were largely in line with theoretical expectations. One partial exception concerned the limited discriminant validity of the MPQ-Meanness and Disinhibition scales. On balance, the present findings suggest that the MPQ-Tri scales fulfill their intended purpose, with some noted limitation, and provide grounds for the use of the MPQ-Tri scales in developmentally-informed studies on the etiology and consequences of psychopathy. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.